Overview of each patient’s characteristics: part 2
| Pt . | Experimental treatment . | ICU treatment . | Absolute count of neutro-phils at baseline, ×109/L . | Highest grade of neutro-penia . | Highest grade of lympho-penia . | Highest CrP level in mg/L (normal <5) . | Highest IL−6 level in ng/L (normal <7) . | Highest PCT level in µg/L (normal <0.5) . | Highest ferritin level in µg/L (normal male: 22-322, normal female: 10-291) . | SARS-CoV-2 IgM/IgG . | Days until no detectable SARS-CoV-2 RNA in naso-pharyngeal swabs* . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type of MV (days) . | Vaso-pressor therapy . | Renal replacement therapy . | |||||||||||
| 1 | Lopinavir/ ritonavir, Pentaglobin | HFNC (1), MV (4) | Yes | No | 7.7 | Grade 3 | Grade 3 | 246 | 526 | 0.8 | 1 514 | Negative/negative | 32 |
| 2 | None | HFNC (1), MV (8) | Yes | Yes | 0.1 | Aplasia | Grade 4 | 259 | 5250 | 11.84 | 12 436 | ND/ND | Positive until death |
| 3 | COVID-19 convalescent plasma | NA | NA | No | 1.5 | Grade 3 | Grade 3 | 183 | 109 | 0.09 | 4 006 | Positive/positive | Positive until end of study |
| 4 | None | None | No | No | 0.1 | Aplasia | Grade 4 | 215 | 447 | 0.59 | 6 268 | Positive/positive | 22 |
| 5 | Tocilizumab, Pentaglobin | HFNC (1), MV (9), ECMO (5) | Yes | Yes | 0.3 | Aplasia | Grade 4 | 291 | 8452 | 2.87 | 21 173 | ND/ND | Positive until death |
| 6 | None | None | No | No | <0.1 | Aplasia | Grade 4 | 292 | 287 | 1.87 | 3 204 | Negative/negative | 22 |
| 7 | None | HFNC (1), MV (12) | Yes | Yes | 11.3 | Aplasia | Grade 3 | 368 | 1513 | 6.71 | 4 431 | Positive/positive | 36 |
| 8 | None | None | No | No | 0.1 | Aplasia | Grade 3 | 163 | 72 | 0.27 | 2 413 | Positive/positive | 33 |
| 9 | None | None | No | No | 0.1 | Aplasia | Grade 4 | 270 | 1338 | 4.76 | 11 911 | Positive/positive | Positive until end of study |
| 10 | None | HFNC (5) | No | No | 0.6 | Aplasia | Grade 4 | 333 | 768 | 16.7 | 15 357 | Positive/positive | 29 |
| 11 | None | MV (4) | Yes | No | 1.1 | Aplasia | Grade 3 | 361 | 538 | 4.86 | 2 888 | Positive/negative | 12 |
| 12 | None | NA | NA | No | 1.2 | Grade 3 | Grade 3 | 4 | 1.6 | 0.1 | 1 385 | Negative/negative | 29 |
| Pt . | Experimental treatment . | ICU treatment . | Absolute count of neutro-phils at baseline, ×109/L . | Highest grade of neutro-penia . | Highest grade of lympho-penia . | Highest CrP level in mg/L (normal <5) . | Highest IL−6 level in ng/L (normal <7) . | Highest PCT level in µg/L (normal <0.5) . | Highest ferritin level in µg/L (normal male: 22-322, normal female: 10-291) . | SARS-CoV-2 IgM/IgG . | Days until no detectable SARS-CoV-2 RNA in naso-pharyngeal swabs* . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type of MV (days) . | Vaso-pressor therapy . | Renal replacement therapy . | |||||||||||
| 1 | Lopinavir/ ritonavir, Pentaglobin | HFNC (1), MV (4) | Yes | No | 7.7 | Grade 3 | Grade 3 | 246 | 526 | 0.8 | 1 514 | Negative/negative | 32 |
| 2 | None | HFNC (1), MV (8) | Yes | Yes | 0.1 | Aplasia | Grade 4 | 259 | 5250 | 11.84 | 12 436 | ND/ND | Positive until death |
| 3 | COVID-19 convalescent plasma | NA | NA | No | 1.5 | Grade 3 | Grade 3 | 183 | 109 | 0.09 | 4 006 | Positive/positive | Positive until end of study |
| 4 | None | None | No | No | 0.1 | Aplasia | Grade 4 | 215 | 447 | 0.59 | 6 268 | Positive/positive | 22 |
| 5 | Tocilizumab, Pentaglobin | HFNC (1), MV (9), ECMO (5) | Yes | Yes | 0.3 | Aplasia | Grade 4 | 291 | 8452 | 2.87 | 21 173 | ND/ND | Positive until death |
| 6 | None | None | No | No | <0.1 | Aplasia | Grade 4 | 292 | 287 | 1.87 | 3 204 | Negative/negative | 22 |
| 7 | None | HFNC (1), MV (12) | Yes | Yes | 11.3 | Aplasia | Grade 3 | 368 | 1513 | 6.71 | 4 431 | Positive/positive | 36 |
| 8 | None | None | No | No | 0.1 | Aplasia | Grade 3 | 163 | 72 | 0.27 | 2 413 | Positive/positive | 33 |
| 9 | None | None | No | No | 0.1 | Aplasia | Grade 4 | 270 | 1338 | 4.76 | 11 911 | Positive/positive | Positive until end of study |
| 10 | None | HFNC (5) | No | No | 0.6 | Aplasia | Grade 4 | 333 | 768 | 16.7 | 15 357 | Positive/positive | 29 |
| 11 | None | MV (4) | Yes | No | 1.1 | Aplasia | Grade 3 | 361 | 538 | 4.86 | 2 888 | Positive/negative | 12 |
| 12 | None | NA | NA | No | 1.2 | Grade 3 | Grade 3 | 4 | 1.6 | 0.1 | 1 385 | Negative/negative | 29 |
Neutropenia: grade 2, <1.5 × 109/L to 1.0 × 109/L; grade 3, <1.0 × 109/L to 0.5 × 109/L; aplasia, <0.5 × 109/L. Lymphopenia: grade 1, 1.1 × 109/L to 0.8 × 109/L; grade 2, <0.8 × 109/L to 0.5 × 109/L; grade 3, <0.5 × 109/L to 0.2 × 109/L; grade 4, <0.2 × 109/L.
CrP, C-reactive protein; HFNC, high-flow nasal cannula; IL-6, interleukin-6; MV, mechanical ventilation; PCT, procalcitonin. See Table 1 for expansion of other abbreviations.
Two negative PCR results >24 hours.